Delivery Order SPE2DB24D1205-SPE2DB25FCZSL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units, with a ceiling value of $5,252.73. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count units) with a ceiling value of $4,885.54. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is scheduled for completion by August 20, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order valued at $11,862.80, with an ultimate completion date of August 15, 2025. The order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron Orally Disintegrating Tablets 4mg in a quantity of 30 tablets. This is a firm fixed-price delivery order with a ceiling value of $52,217.75 and an ultimate completion date of September 10, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $8,962.67 under a firm fixed price structure, with an ultimate completion date of August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ondansetron Orally Disintegrating Tablets 4mg in a quantity of 30 tablets. This is a firm fixed price delivery order valued at $6,666.32 with an ultimate completion date of September 11, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a contract ceiling value of $1,961.44. This firm fixed price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999.99 billion through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $28,456.56 on August 15, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. The contract employs firm fixed pricing and carries an ultimate completion date of August 18, 2025. This delivery order is issued without a set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZSLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units. This is a firm fixed-price delivery order with a ceiling value of $9,303.33 and an ultimate completion date of August 20, 2025. The contract is non-competitive and represents a direct purchase under AmerisourceBergen's existing indefinite delivery contract framework. The place of performance is listed as Conshohocken, Pennsylvania, which is the company's corporate headquarters location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical prime vendor for the Defense Health Agency and other federal healthcare systems, supplying a comprehensive range of pharmaceuticals, medical supplies, and specialty medications to support military and veteran healthcare programs globally. Ondansetron is an antiemetic commonly used in military medical supply chains for surgical and chemotherapy-related nausea management.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.3k | 8/19/25 |